Home Junshi Biosciences: Toripalimab Phase III NEOTORCH Study Meets All Primary Endpoints in Resectable Stage II-III NSCLC

Junshi Biosciences: Toripalimab Phase III NEOTORCH Study Meets All Primary Endpoints in Resectable Stage II-III NSCLC

May 26, 2026 18:19 CST Updated 19:18
Junshi Biosciences

Innovative Drug Developer